Connect with us

Technology

FinnGen Selects Azenta to Propel Personalized Medicine for Population Health Study

Published

on

Azenta will provide proteomics technology profiling on up to 20,000 individuals.

BURLINGTON, Mass., July 22, 2024 /PRNewswire/ — Azenta, Inc. (Nasdaq: AZTA) today announced its participation in the FinnGen project, a large-scale research initiative at the forefront of personalized medicine in Finland. The FinnGen project is a pioneering endeavor that has collected and is currently analyzing genomic and health data from a cohort of 500,000 Finnish biobank participants.

In collaboration with the University of Helsinki, the organization leading the FinnGen study, Azenta will provide comprehensive proteomics profiling on up to 20,000 individuals, underscoring Azenta’s commitment to advancing healthcare innovation and personalized treatments. Azenta will use Olink’s advanced proteomics technology, based on the proprietary Proximity Extension Assay, to provide high-quality protein-level measurements across all major biological pathways.

“FinnGen’s adoption of proteomics marks a pivotal advancement in our quest to decode the complexities of human health and disease. By integrating the dynamic insights of proteomics with our extensive genomic data, we can gain a deeper understanding of disease mechanisms, identify new biomarkers for early detection, and uncover novel therapeutic targets. We are pleased to collaborate with Azenta Life Sciences, and trust that they will provide excellent service and deliver high-quality proteomic data with a fast turnaround time,” said Professor Aarno Palotie, FinnGen Scientific Director from the Institute for Molecular Medicine Finland (FIMM), University of Helsinki. “Combined with excellent quality and reliable results, Azenta Life Sciences can help us construct a strong foundation for advancing the field of personalized medicine.”

“As one of the collaborators in the FinnGen Project, Azenta looks forward to making meaningful contributions to personalized medicine and revolutionizing healthcare for generations to come,” said Ginger Zhou, PhD., Senior Vice President and General Manager, GENEWIZ Multiomics & Synthesis Solutions from Azenta Life Sciences. “Multiomics technologies from Azenta enable researchers to efficiently generate detailed proteomics data from study participants carrying medically and clinically significant genetic variants, opening up a world of possibilities for understanding disease mechanisms and developing targeted treatments.”

About FinnGen

FinnGen is a large public-private partnership aiming to collect and analyze genome and health data from 500,000 Finnish biobank participants. FinnGen aims on one hand to provide novel medically and therapeutically relevant insights but also construct a world-class resource that can be applied for future studies.

FinnGen is one of the very first personalized medicine projects at this scale and the public-private collaborative nature of the project is exceptional compared to many ongoing studies. FinnGen brings together Finnish universities, hospitals and hospital districts, THL, Blood Service, biobanks, FINBB and international pharmaceutical companies and hundreds of thousands of Finns. Because collaboration is the key to achieving breakthroughs in disease prevention, diagnosis, and treatment, we welcome everyone on this journey into our shared heritage.

For more information, please visit https://www.finngen.fi/en.

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research, and advanced cell therapies for the industry’s top pharmaceutical, biotech, academic, and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey and B Medical Systems.

Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

“Safe Harbor Statement” under Section 21E of the Securities Exchange Act of 1934

Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta’s financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. Other forward-looking statements include but are not limited to statements about the prospects of the FinnGen Project and our ability to contribute to the advancement of personalized medicine. Factors that could cause results to differ from our expectations include the following: changes in technology and/or science that impact our ability to enable researchers to generate the proteomics data required to understand disease and develop targeted treatments and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, Current Reports on Form 8-K and our Quarterly Reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release.

INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor Relations
ir@azenta.com

Sherry Dinsmore
sherry.dinsmore@azenta.com

Azenta’s use of third-party trademarks and brands are for identification only and does not imply affiliation or endorsement. All trademarks used herein are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/finngen-selects-azenta-to-propel-personalized-medicine-for-population-health-study-302203113.html

SOURCE Azenta

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Kratos Capital Announces Acquisition of Weldon Services by Upchurch Services, LLC

Published

on

By

This acquisition strengthens Upchurch’s market position while unlocking new growth potential for Weldon Services.

DALLAS, Sept. 27, 2024 /PRNewswire-PRWeb/ — Kratos Capital, a leading mergers and acquisitions advisor for privately held, middle-market businesses, is pleased to announce the successful acquisition of Weldon Services by Upchurch Services, LLC, a portfolio company of Broadwing Capital. This strategic acquisition allows Upchurch Services, LLC to enter the highly sought-after Dallas/Fort Worth Metropolitan Statistical Area (MSA), expanding their market presence and service capabilities. The deal was closed on September 12, 2024.

Weldon Services, known for providing exceptional mechanical, electrical, and plumbing (MEP) services across Dallas and Ft. Worth, brings decades of expertise and a strong client base. By joining forces with Upchurch Services, LLC, a prominent provider of specialty contracting services backed by Broadwing Capital, both companies are poised for significant growth.

This acquisition provides Upchurch with an important foothold in the Dallas/Fort Worth MSA, one of the fastest-growing metropolitan areas in the country. The region offers significant opportunities for expansion in commercial and residential markets, and the addition of Weldon Services’ capabilities further strengthens Upchurch’s service offerings in mechanical and electrical contracting.

Kratos Capital, a trusted name in managing complex M&A transactions, facilitated the deal, ensuring a seamless integration of Weldon Services into the Upchurch portfolio. The partnership between Weldon Services and Upchurch Services, LLC is expected to create new opportunities for both companies while enhancing their ability to deliver top-tier services to clients in the region.

Additional information regarding Kratos Capital, its M&A services, and previous M&A dealings can be found on the company website.

Kratos Capital is a distinguished M&A firm with over a century of combined experience in the industry, dedicated to exceeding client expectations through expertly crafted exit strategies that maximize shareholder value. Serving clients across the United States, Canada, and South America, they specialize in enhancing the sale and divestiture process using proprietary technology and a principal mentality to ensure successful and satisfying transitions.

Media Contact

Josh Bammel, Kratos Capital, 1 (214)684-9101, josh@kratoscap.comhttps://www.kratoscapital.com/

View original content to download multimedia:https://www.prweb.com/releases/kratos-capital-announces-acquisition-of-weldon-services-by-upchurch-services-llc-302259591.html

SOURCE Kratos Capital

Continue Reading

Technology

AT&T Declares Dividends on Common and Preferred Shares

Published

on

By

DALLAS, Sept. 27, 2024 /CNW/ — The board of directors today declared a quarterly dividend of $0.2775 per share on the company’s common shares, payable November 1, 2024.

Key Takeaways:

The board of directors declared a quarterly dividend of $0.2775 per share on the company’s common shares.Dividends on common stock as well as Series A and Series C preferred stock are payable on November 1, 2024.

The board of directors of AT&T (NYSE: T) today declared a quarterly dividend of $0.2775 per share on the company’s common shares.

The board of directors also declared quarterly dividends on the company’s 5.000% Perpetual Preferred Stock, Series A and the company’s 4.750% Perpetual Preferred Stock, Series C. The Series A dividend is $312.50 per preferred share, or $0.3125 per depositary share. The Series C dividend is $296.875 per preferred share, or $0.296875 per depositary share.

Dividends on the common stock and Series A and Series C preferred stock are payable on November 1, 2024, to stockholders of record of the respective shares at the close of business on October 10, 2024.

About AT&T

We help more than 100 million U.S. families, friends and neighbors, plus nearly 2.5 million businesses, connect to greater possibility. From the first phone call 140+ years ago to our 5G wireless and multi-gig internet offerings today, we @ATT innovate to improve lives. For more information about AT&T Inc. (NYSE:T), please visit us at about.att.com. Investors can learn more at investors.att.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/att-declares-dividends-on-common-and-preferred-shares-302261477.html

SOURCE AT&T

Continue Reading

Technology

Renal Support Network to Host 31st Annual Kidney Disease Education and Lifestyle Meeting Virtually

Published

on

By

Hope Week 2024 Offers Five Days of Inspiration, Education, and Support for People Living with Kidney Disease, Their Families, and Healthcare Professionals

GLENDALE, Calif., Sept. 27, 2024 /PRNewswire-PRWeb/ — Renal Support Network (RSN) will host its 31st Annual Kidney Disease Education and Lifestyle Meeting from October 9th-13th, 2024. For over three decades, RSN has hosted this highly regarded event, providing education, resources, and support for people living with kidney disease, their families, and healthcare professionals. This event, aptly named Hope Week, will continue this tradition with a focus on fostering hope and empowerment for those affected by kidney disease.

RSN Founder/ President Lori Hartwell reflects, “Fear arises from a lack of understanding, and loneliness can be eased by connecting with a community that truly understands what you’re going through. Hope Week addresses these challenges. Knowledge and confidence in navigating care is within reach.”

Each day of the event will center on a different stage or aspect of chronic kidney disease (CKD), covering topics such as diagnosis, dialysis, kidney transplant, and daily lifestyle challenges. Esteemed healthcare professionals, along with those from within the kidney community who have learned to thrive in spite of having kidney disease, will share their expertise, advice, and personal stories, offering valuable insight into living and thriving with CKD.

RSN remains committed to equitable access to information and resources, ensuring that no individual faces barriers to participation. By utilizing a virtual platform, the meeting allows those who may face physical, geographic, or financial constraints to engage fully in the event.

Hope Week provides not only education but also inspiration and a chance to connect with a supportive community of people who have been there. It’s a unique opportunity to hear firsthand from those who have walked the path and to learn about the latest advancements in kidney care.

RSN Founder and President Lori Hartwell reflects, “Throughout my journey—marked by more than 50 surgeries, 13 years on dialysis, and four kidney transplants—I’ve faced some of life’s toughest lessons. These were not the lessons you learn in school, but ones born from personal experience. I know many of my peers share the same fears and feelings of isolation that I’ve experienced. Fear often arises from a lack of understanding, and loneliness can be eased by connecting with a community that truly understands what you’re going through. That’s exactly what Hope Week provides: five days of inspiration and education designed to address these challenges. One of the cornerstones of RSN is the motto, ‘an illness is too demanding when you don’t have hope’, and Hope Week is here to remind everyone that connection, knowledge and confidence in navigating care is within reach.”

Key Event Highlights:

There are no fees to attend.

Free Gift for Attending: All attendees receive a complimentary gift from RSN.

The event starts later in the afternoon on the weekdays so that people who work can attend.

Daily Focused Sessions: Each day will highlight a different stage or aspect of CKD, including topics such as diagnosis, dialysis, kidney transplants, and the management of daily lifestyle issues.

Expert Speakers and Panelists: Renowned healthcare professionals and experts from the kidney community will offer advice and discuss the latest developments in kidney care.

Patient and Caregiver Stories: Attendees will have the opportunity to hear inspiring personal stories from patients and caregivers who have firsthand experience managing CKD.

Interactive Q&A Sessions: Participants will be able to engage directly with speakers and panelists, asking questions and gaining insight into various aspects of kidney disease management.

Access for All: The virtual platform ensures that individuals from across the globe can participate, regardless of their location or circumstances.

Networking and Support: Hope Week will also feature opportunities to connect with others who are experiencing similar challenges, creating a supportive and uplifting environment.

Youth and Family Day: Parents share their tips for coping with challenges of a busy family life and young adults share their stories about transitioning to adulthood, finding independence, a career, dating and school.

Lifestyle Expo: Explore virtual booths featuring kidney-friendly products, services, and resources.

To see the full agenda and to register go to RSNHope.org/HopeWeek.

RSN would like to thank our 2024 Hope Week sponsors: Akebia, Amgen, Alexion, Ardelyx, AstraZeneca and U.S. Renal Care.

The Renal Support Network is a Registered 501(c)(3) Non-profit and serve people throughout the United States.

Lori Hartwell founded Renal Support Network in 1993 to empower people who have kidney disease to become knowledgeable about their illness, proactive in their care, hopeful about their future and make friendships that last a lifetime. Lori suffered kidney failure at the age of two, survived 50+ surgeries and 13 years of dialysis, and is now living with her fourth kidney transplant.

RSN’s hopeful and life-enriching, non-medical programs help people who have kidney disease and their families, whether they are in the early stages of the disease, are on dialysis, or have received a transplant. www.RSNhope.org.

Media Contact

Suzette Maffi, Renal Support Network, 1 (818) 543-0896, Info@RSNhope.org, https://www.rsnhope.org/

View original content to download multimedia:https://www.prweb.com/releases/renal-support-network-to-host-31st-annual-kidney-disease-education-and-lifestyle-meeting-virtually-302259594.html

SOURCE Renal Support Network

Continue Reading

Trending